AstraZeneca PLC AZN StarRatingValueLabel_3Damien Conover, CFA - Sector Director - Morningstar Inc.

Latest Morningstar Commentary
DateAuthor Headline
19/02/2024Jocelyn Jovene Europe's Magnificent 7 Stocks Are Profitable - And Cheaper
Four years ago analysts at Goldman Sachs came up with the GRANOLAS acronym for Europe's leading stocks
24/11/2020Damien Conover Covid Vaccine Breakthrough: the Morningstar View
Morningstar analyst Damien Conover looks in detail at the latest vaccine developments from AstraZeneca and Pfizer/BioNTech
29/10/2019James Gard Brexit Investment Strategies for Uncertain Times
With a General Election slated for December and Brexit postponed until 2020, investors should consider how their portfolios are positioned for more months of uncertainty 
24/07/2019James Gard Glaxo's Vaccines Division Outperforms
FTSE 100 dividend stalwart posts steady results in the first six months and expects better performance in the second half, during which the joint venture with Pfizer will complete

Latest Company News

DateTimeSourceHeadlineType
Previous Stories...
22/05/202408:53ANLONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN
21/05/202416:04ANLONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading
21/05/202411:03ANCORRECT: Stocks fall but pound up as IMF ups UK forecast
21/05/202411:00ANLONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast
21/05/202408:04ANLONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall
21/05/202407:18ANTOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim
21/05/202406:52ANLONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident
21/05/202406:00LSEAstraZeneca to deliver $80bn revenue by 2030MSC
20/05/202410:55ANLONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes
20/05/202407:24ANTOP NEWS: AstraZeneca plans to build manufacturing plant in Singapore
20/05/202406:47ANLONDON BRIEFING: Keywords would back GBP2.0 billion bid as EQT circles
20/05/202406:00LSEAstraZeneca to manufacture ADCs in SingaporeMSC
16/05/202409:27ANAstraZeneca trials yield positive results for immunocompromised patients
16/05/202406:00LSESUPERNOVA Trial Met COVID-19 prevention endpointRES
15/05/202414:00LSEDirector/PDMR ShareholdingDSH
08/05/202408:44ANAstraZeneca says withdraws Covid vaccine "for commercial reasons"
08/05/202408:39ANLONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral
07/05/202408:51ANLONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered
07/05/202406:00LSEAstraZeneca completes Cellectis equity investmentMSC
06/05/202406:46ANAstraZeneca completes collaboration and investment deal with Cellectis
Damien Conover, CFA - Sector Director - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures